#United States #New York #Pomerantz LLP #Bausch + Lomb #BLCO

Pomerantz Law Firm Investigates Bausch + Lomb Corporation

The legal landscape surrounding Bausch + Lomb Corporation (NYSE: BLCO) has intensified as the Pomerantz Law Firm embarks on an investigation into potential claims on behalf of the company's investors. The investigation arises amidst serious concerns regarding possible securities fraud and unlawful business practices associated with the company.

Recent Developments

On March 27, 2025, Bausch + Lomb made headlines when it voluntarily recalled intraocular lenses from its enVista platform. This recall was triggered by alarming reports of toxic anterior segment syndrome—a serious complication potentially linked to cataract surgeries. The fallout from this announcement was immediate; in just two trading sessions, Bausch + Lomb’s stock price plummeted by $1.54 per share, marking a decline of nearly 10%, ultimately closing at $14.13 per share by March 28, 2025.

The situation further deteriorated on April 30, 2025, as the company disclosed its financial results for the first quarter. Bausch + Lomb reported an adjusted net loss of $54 million, starkly contrasting with an adjusted net income of $24 million for the same period last year. Adding to investor concerns, the company revised its growth outlook for the full year, projecting a mere 4.5% to 6.5% year-over-year increase—down from a prior estimate of 5.5% to 7.5%. This downgrade was notably attributed to the repercussions of the enVista product recall.

Following these revelations, the company’s stock faced another significant decline, dropping by $2.16 per share (approximately 15.74%), closing at $11.56 on April 30, 2025. These financial and operational setbacks have spurred Pomerantz LLP to investigate whether Bausch + Lomb's executives and directors acted unlawfully, taking steps that could have put investors at risk.

About Pomerantz LLP

Recognized as a leading firm specializing in corporate, securities, and antitrust class litigation, Pomerantz LLP brings over 85 years of experience to the table. Founded by the late Abraham L. Pomerantz, a figure known for his pivotal role in the evolution of securities class actions, the firm has a robust history of defending the rights of investors against corporate misconduct. Pomerantz continues to advocate for those adversely affected by securities fraud and fiduciary breaches, recovering substantial damages on behalf of affected parties.

Investors’ Next Steps

Investors who are concerned about the potential implications of these investigations or believe they have been negatively impacted are encouraged to reach out to Pomerantz LLP. Danielle Peyton can be contacted via email at [email protected] or by phone at 646-581-9980, ext. 7980. Joining the ongoing class action can provide a platform for voicing grievances and pursuing legal action if warranted. The firm’s emphasis on victim support in litigation underscores its commitment to justice for investors.

Conclusion

As the investigation unfolds, stakeholders will be closely monitoring developments regarding Bausch + Lomb and Pomerantz LLP's continuing efforts. These events serve as a critical reminder of the standards to which public companies, especially in the healthcare sector, must adhere when it comes to transparency and accountability in their business practices. Investors are urged to stay informed and take necessary actions to safeguard their interests in light of these serious allegations.